1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Backlog
URL Address
<a href="http://doi.org/10.1002/ana.410270112" target="_blank" rel="noreferrer">http://doi.org/10.1002/ana.410270112</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Naltrexone therapy of apnea in children with elevated cerebrospinal fluid beta-endorphin
Publisher
An entity responsible for making the resource available
Annals Of Neurology
Date
A point or period of time associated with an event in the lifecycle of the resource
1990
Subject
The topic of the resource
Child; Female; Humans; infant; Male; Prospective Studies; Preschool; infant; Biomarkers of Pain; Newborn; beta-Endorphin/cerebrospinal fluid; Leigh Disease/cerebrospinal fluid; Naltrexone/therapeutic use; Sleep Apnea Syndromes/cerebrospinal fluid/drug therapy
Creator
An entity primarily responsible for making the resource
Myer EC; Morris DL; Brase DA; Dewey WL; Zimmerman AW
Description
An account of the resource
Previous studies have indicated increased immunoreactivity of the endogenous opioid peptide beta-endorphin in the cerebrospinal fluid (CSF) of infants under 2 years of age with apnea. To assess the role of endogenous opioids in the pathogenesis of apnea in children, the effect of oral treatment with the opioid antagonist naltrexone was studied in apneic infants, as well as in older apneic children, with demonstrated increases in CSF immunoreactive beta-endorphin (i-BE). In the 8 apneic infants with elevated i-BE in lumbar CSF (range, 55-155 pg/ml; normal, 17-52 pg/ml), no further apnea occurred during naltrexone therapy (1 mg/kg/day, by mouth). Five children (2-8 years old) with apnea of unknown cause had elevated CSF i-BE (range, 74-276 pg/ml) compared to 6 age-matched nonapneic children (range, 15-48 pg/ml). No apneic events occurred during naltrexone therapy, except in 1 child during stressful events, but apnea recurred in some patients after attempts to discontinue naltrexone treatment. Adverse effects of naltrexone included complaints of headaches in 2 children and symptoms of a narcotic withdrawal syndrome during the first 3 days of treatment in 1 child. Three children with Leigh's syndrome had elevated CSF i-BE (range, 104-291 pg/ml) and their apnea also responded to naltrexone. We conclude that elevated endogenous opioids contribute to the pathogenesis of apnea in children and may even result in physical dependence.
1990
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1002/ana.410270112" target="_blank" rel="noreferrer">10.1002/ana.410270112</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
The nature or genre of the resource
Journal Article
1990
Annals Of Neurology
Backlog
beta-Endorphin/cerebrospinal fluid
Biomarkers of Pain
Brase DA
Child
Dewey WL
Female
Humans
Infant
Journal Article
Leigh Disease/cerebrospinal fluid
Male
Morris DL
Myer EC
Naltrexone/therapeutic use
Newborn
Preschool
Prospective Studies
Sleep Apnea Syndromes/cerebrospinal fluid/drug therapy
Zimmerman AW